Percheron Therapeutics Ltd News

Percheron Therapeutics Ltd: Notification regarding unquoted securities - PER

Jul 4 02:42 ET

Percheron Therapeutics Ltd: Deborah Ambrosini appointed as CFO & Company Secretary

Jun 16 19:04 ET

Percheron Therapeutics Ltd: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor

Jun 2 18:31 ET

Percheron Therapeutics Ltd: Percheron to present at 2024 BIO International Convention

May 30 18:32 ET

Percheron Therapeutics Ltd: Phase IIb study of ATL1102 in DMD completes recruitment

May 28 19:01 ET

Percheron Therapeutics Ltd: Preliminary Results of 9 Month Toxicology Study of ATL1102

May 26 19:41 ET

Percheron Therapeutics Ltd: US Patent Granted for ATL1102 in Duchenne muscular dystrophy

May 19 18:41 ET

Percheron Therapeutics Ltd: WHO selects proposed INN for ATL1102

May 5 18:52 ET

Percheron Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Apr 29 18:53 ET

Percheron Therapeutics Ltd: Change in substantial holding

Apr 26 02:59 ET

Percheron Therapeutics Ltd: ATL1102 Clinical Trial Update

Apr 1 18:07 ET

Percheron Therapeutics Ltd: ATL1102 Data presented at MDA Annual Conference

Mar 3 16:49 ET

Percheron Therapeutics Ltd: Half Yearly Report and Accounts

Feb 28 01:20 ET

Percheron Therapeutics Ltd: Percheron Therapeutics Limited Corporate Presentation

Feb 25 16:27 ET

Percheron Therapeutics Ltd: Change of Registered Office and Principal Place of Business

Feb 20 16:22 ET

Percheron Therapeutics Ltd: Receipt of R&D Tax incentive payment

Feb 11 16:39 ET

Percheron Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jan 30 17:12 ET

Percheron Therapeutics Ltd: ATL1102 DMD Phase IIA Final Data Published

Jan 28 16:28 ET